Study Details

Open

Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors

This study will look at the safety and effectiveness of combining two or three experimental anti-cancer drugs, referred to as tislelizumab (also known as BGB-A317), BGB-A425, and/or LBL-007.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Extended hours (M-F, early morning or evening)

Location

North Carolina (Statewide)

What will be asked of you

This study aims to treat your cancer and closely resembles routine care that would be received regardless of participating on a research study. To participate on the study, you will meet frequently with a member of the study team in addition to your oncology care team. There will be weekly visits for the first 3 weeks. The study involves routine blood work and diagnostic tests. You will receive treatment with BGB-A425 and Tislelizumab intravenously.

Incentives

In-person visits:
16

Total length of participation:
About 2 years

Looking for Specific Volunteers

Able to participate:

No prior systemic treatment for metastatic NSCLC
Are at least 18 years old
You have previously received immunotherapy
You have histologically or cytologically documented locally advanced or recurrent non-small cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive radiotherapy
You agree to provide archival tissue or fresh biopsy (if archival tissue is not available).

Not eligible if:

You have received prior therapy or treatment tagerting TIM-3.
You have received more than three lines of therapy.
You have history of HIV infection or untreated, chronic hepatitis B or C.
You have known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.
You have active leptomeningeal disease or uncontrolled, untreated brain metastasis.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Sid Sheth
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Head and Neck, Lung)

IRB Number

20-1656

ClinicalTrials.gov

NCT03744468